On June 18, Insilico Medicine rose 5.05% in regular trading, trading at HK$35.08/share, with turnover of HK$34.16 million.

On the news front, the rally extends the positive momentum from the previous trading day's announcement that ISM8969, co-developed with Hygtia Therapeutics (Shenzhen Hengtai Biotech), completed first-in-human dosing in its Phase I clinical trial, achieving the first clinical milestone under their collaboration. ISM8969 is a potentially best-in-class oral small-molecule NLRP3 inflammasome inhibitor capable of penetrating the blood-brain barrier, targeting chronic neuroinflammation and CNS diseases including Parkinson's disease. Under the agreement, both parties hold 50% global rights, and Insilico Medicine is entitled to receive up to US$66 million in upfront and milestone payments.

At the sector level, the Life Sciences Tools & Services sector showed broad strength today, with Wuxi Biologics up 3.42%, Wuxi AppTec up 3.43%, and GenScript Biotech up 3.19%, providing additional tailwind to sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)